ARBINOXA ORAL SOLUTION Rx
Generic Name and Formulations:
Carbinoxamine maleate 4mg/5mL; bubble gum flavor.
Indications for ARBINOXA ORAL SOLUTION:
Allergic (seasonal and perennial) and vasomotor rhinitis, conjunctivitis, urticaria, angioedema, reactions to blood. Adjunct in anaphylaxis. Dermatographism.
4–8mg 3–4 times daily.
<2yrs: contraindicated. 2–5yrs: 0.2–0.4mg/kg/day in 3–4 divided doses. 6–11yrs: 2–4mg 3–4 times daily.
Children <2yrs old. Concomitant MAOIs. Nursing mothers.
Not for treating lower respiratory tract symptoms, including asthma. Narrow angle glaucoma. Peptic ulcer. GI or GU obstruction. Increased intraocular pressure. Hyperthyroidism. Cardiovascular disease. Hypertension. Elderly. Pregnancy (Cat.C).
CNS depression potentiated by alcohol (avoid), other CNS depressants. MAOIs potentiate anticholinergic effects.
Sedation, sleepiness, dizziness, disturbed coordination, GI upset, thickening of bronchial secretions, anticholinergic effects, excitability in children.
Tabs—100; Oral soln—16oz
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Prediction Algorithm Stratifies ICH Patients at Risk for Hematoma Expansion
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- Psychological Therapies May Help Older Adults With Chronic Pain
- Traumatic Brain Injury Linked to Increased Parkinson Disease Risk in Veterans
- Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics